Sign in Subscribe
COVID-19

Advancements in mRNA Delivery: Beyond Lipid Nanoparticles

Strategic Insights

— 1 min read

Research conducted by the Helmholtz-Institute for Pharmaceutical Research Saarland has shed light on the limitations of lipid nanoparticles (LNPs) in delivering mRNA-based vaccines. Despite their clinical success, LNPs possess several inherent limitations, including instability and toxicity. The study aims to address these challenges by exploring novel materials, such as poly(beta-amino esters) (PBAEs) and alternative lipid components, as well as hybrid nanoparticle systems designed to enhance delivery efficiency and reduce toxicity.

Key Takeaways:

  • The study highlights the importance of improving mRNA stability and translational efficiency, including formulation stabilization through lyophilization.
  • Researchers discussed strategies to replace PEG-lipids with alternative lipid components to reduce toxicity.
  • The study also analyzed novel materials, such as PBAEs, to enhance delivery efficiency and enable tissue-specific targeting.
  • Different targeting strategies, including passive and active nanoparticle-mediated delivery, were compared to approaches based on novel medical devices, such as inhalers or microneedles.
  • The study addresses advancements in manufacturing technologies tailored for personalized medicine, alongside analytical, regulatory, and intellectual property considerations critical for the development and commercialization of next-generation mRNA formulations.
  • The research was carried out by a team led by Aljoscha Gabelmann from the Helmholtz-Institute for Pharmaceutical Research Saarland, in collaboration with Achim Biesel, Brigitta Loretz, and Claus-Michael Lehr.

Statistics:

  • Over six decades of fundamental research and technological innovation have led to the emergence of LNPs as the gold standard for mRNA delivery.
  • The COVID-19 pandemic highlighted the rapid development of mRNA-based vaccines using LNPs.
  • The study analyzed novel materials, such as PBAEs, to enhance delivery efficiency and enable tissue-specific targeting.
  • The research aims to point out solutions to the limitations of LNPs, including formulation stabilization and toxicity reduction.
  • Manufacturing technologies tailored for personalized medicine are critical for the development and commercialization of next-generation mRNA formulations.

Sources:

  • Exploring the future of mRNA delivery: Beyond lipid nanoparticles. Biochemical and Biophysical Research Communications, 2025;778:152347.
  • Academic Press Inc Elsevier Science, 525 B St, Ste 1900, San Diego, CA 92101-4495, USA (Elsevier - www.elsevier.com)
  • Biochemical and Biophysical Research Communications (www.journals.elsevier.com/biochemical-and-biophysical-research-communications/)
  • Helmholtz-Institute for Pharmaceutical Research Saarland, Campus E8.1, 66123, Saarbrucken, Germany

Read more